Literature DB >> 2900339

Efficacy of a single dose of secnidazole in the treatment of acute and chronic amoebiasis.

A A Latonio1.   

Abstract

An open study was carried out to determine the clinical efficacy of secnidazole in the treatment of acute and chronic cases of amoebiasis. Patients were given 2 g of secnidazole in a single dose or in two divided doses within a 4 h interval. Details were recorded daily by patients of complaints such as fever, lumbar pain, LBM, dizziness, body weakness, bloody mucoid stools, epigastric pains and other symptoms, before and after treatment. Results were analysed for 45 chronic and five acute cases and showed clinical cure of 98% in chronic and 80% in acute cases. The acute group showed a non-significant change (P greater than 0.05) which could be attributed to the small sample size. The treatment regimen proved effective for the eradication of E. histolytica and only two (4%) remained positive after treatment out of the 50 patients initially positive.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2900339

Source DB:  PubMed          Journal:  J Trop Med Hyg        ISSN: 0022-5304


  2 in total

Review 1.  Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis.

Authors:  J C Gillis; L R Wiseman
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

2.  Efficacy and Safety of Quinfamide versus Secnidazole in the Management of Amoebic Non-Dysenteric Colitis in Children.

Authors:  N Padilla; R Díaz; M Muñoz
Journal:  Clin Drug Investig       Date:  2000       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.